A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial
Metrics: PDF 148 views | Full Text 277 views | ?
Guillermo de Velasco1, Lucia Carril-Ajuria1, Felix Guerrero-Ramos2, Teresa Alonso-Gordoa3, Juan F. Rodríguez-Moreno4, Alberto Carretero1, Maricruz Martin-Soberon1, Federico de la Rosa-Kehrmann2 and Daniel Castellano1
1 Medical Oncology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain
2 Urology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain
3 Medical Oncology Department, Hospital Universitario Ramón y Cajal, Comunidad de Madrid, Madrid, Spain
4 Medical Oncology Department, Hospital Universitario HM Sanchinarro, Comunidad de Madrid, Madrid, Spain
|Guillermo de Velasco,||email:||email@example.com|
Keywords: kidney cancer; renal cell carcinoma; neoadjuvant treatment; cabozantinib; trial
Received: September 18, 2020 Accepted: October 27, 2020 Published: November 24, 2020
Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it should be avoided in most poor-risk patients. Nevertheless, it should still be considered in patients responding to systemic therapy and good-risk patients not requiring systemic treatment.
This case series of the phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may be able to induce rapid and significant responses in some intermediate-risk advanced renal cell carcinoma patients facilitating resectability.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.